RT Journal Article
T1 Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
A1 Mezquita-Raya, Pedro
A1 Darbà, Josep
A1 Ascanio, Meritxell
A1 Ramírez de Arellano, Antonio
K1 Diabetes type 1
K1 ICER
K1 costs
K1 diabetes type 2
K1 effectiveness
K1 hypoglycaemic episodes
K1 insulin degludec
K1 insulin glargine
AB The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. A short-term cost utility model was developed to estimate effectiveness results in terms of the total number of hypoglycaemic events and their disutility impact throughout the year on the initial level of quality of life for patients in each treatment. Degludec was the dominant strategy for T2DM BOT and exhibited an incremental cost-effectiveness ratio of 52.70€/QALY and 11,240.88€/QALY for T1DM B/B and T2DM B/B, respectively. Lower costs are primarily driven by lower nocturnal and severe hypoglycaemic events, which were reduced versus IGlar. Improvements in clinical outcomes in all three patient groups are result of the reduced number of hypoglycaemic events showing 0.0211, 0.0328 and 0.0248 QALYs gained when compared to IGlar for T1DM B/B, T2DM BOT and T2DM B/B, respectively. Different scenario analyses showed that the ICERS were stable to plausible variations in the analysed parameters, except when the same number of SMBG for both treatments is used, with T2DM B/B showing an ICER over the accepted threshold. This analysis demonstrates that degludec is a cost-effective option in the Spanish NHS, when used in patients currently treated with long-acting insulin.
YR 2017
FD 2017-07-03
LK http://hdl.handle.net/10668/11343
UL http://hdl.handle.net/10668/11343
LA en
DS RISalud
RD Apr 6, 2025